

April 8, 2009



JAK2 Competitive Landscape

Event: American Association for Cancer Research, April 18-22,



Leading JAK2 candidates

AstraZeneca (NYSE:AZN): AZD-1480-JAK 2 program
Novel Jak2 inhibitors block Stat3-dependent oncogenesis in solid tumors
Tuesday, Apr 21, 2009, 1:00 PM - 5:00 PM, Hall B-F, Poster Section 36

Onyx (NASDAQ:ONXX)/**S*Bio**: SB1518-JAK2 inhibitor
[S*BIO to get equity investment from Onyx Pharmaceuticals](#)

Cephalon (NASDAQ:CEPH): CEP-701 (Lestaurtinib)- FLT3, JAK2 inhibitor
[Cephalon's lestaurtinib has higher chance of success in polycythaemia vera but data remains premature if FLT3 is a viable target, physicians say \(Pharmawire\)](#)



Unpartnered targets in development

Incyte (NASDAQ:INCY): Market cap USD 219.2m
INCB18424-Jak2 inhibitor

[Incyte's INCB18424 and other JAK2 inhibitors will likely show the greatest benefit in combination therapy, physicians say \(Pharmawire\)](#)
[Incyte's INCB18424 and other JAK2 inhibitors could face FDA approval difficulties based solely on quality of life improvements, physicians speculate \(Pharmawire\)](#)

[Incyte's INCB18424 and other JAK2 inhibitors unlikely to improve upon current standard of care in essential thrombocythemia, physicians say \(Pharmawire\)](#)

[Incyte's INCB18424 and Exelixis' XL019 effects on normal JAK2 could increase thrombocytopenia caused by myelofibrosis \(Pharmawire\)](#)

[Incyte's INCB18424 and Exelixis' XL019 will need to show disease modification at a molecular level for approval in polycythemia vera indication - analysis \(Pharmawire\)](#)

[Incyte's INCB18424 and Exelixis' XL019 should demonstrate a clean side-effect profile in polycythemia vera indication for FDA approval, sources say \(Pharmawire\)](#)

[Incyte's INCB18424 treatment for myelofibrosis may have more side-effects than other JAK2 inhibitors because it is 'less-targeted', competing execs say \(Pharmawire\)](#)

Small molecule inhibitors of JAK1/2 improve physiological and functional measures of cancer-associated cachexia

Monday, Apr 20, 2009, 1:00 PM - 5:00 PM, Hall B-F, Poster Section 34

Resistance to tyrosine kinase inhibitors reversed by selective JAK inhibition

Tuesday, Apr 21, 2009, 1:00 PM - 5:00 PM, Hall B-F, Poster Section 38

Supergen (NASDAQ:SUPG); Market cap USD 100.7m

SGI-1252- Jak2 inhibitor

[SuperGen will not take any compound into Phase III trials if unpartnered, out-licensing pipeline, CEO says \(Pharmawire\)](#)

[SuperGen in talks to partner-out JAK2 inhibitor and aurora kinase inhibitor platform, CMO says \(Pharmawire\)](#)

Exelixis (NASDAQ:EXEL): Market cap USD 506.4m

XL019-selective inhibitor of JAK2

[Exelixis's XL019 may be disadvantaged in clinical development compared to other JAK2 inhibitors due to side-effect of neuropathy, clinicians say \(Pharmawire\)](#)

TargeGen-Raised USD 40 m in Series D Financing July 2007

TG101348 -Jak2, Flt3, Ret inhibitor

[TargeGen's TG101348, may not be much more efficacious and safe compared to other JAK2 inhibitors despite specific effect on the JAK2V617F mutation, physicians say \(Pharmawire\)](#)

[TargeGen willing to partner JAK2 inhibitor for development in variety of hematological malignancies, CEO says \(Pharmawire\)](#)

Co-treatment with pan-HDAC inhibitor panobinostat or heat shock protein (hsp) 90 inhibitor AUY922 with JAK2 inhibitor TG101209 is highly active against bone marrow progenitor cells from myeloproliferative neoplasms (MPN)

Tuesday, Apr 21, 2009, 8:00 AM -12:00 PM , Hall B-F, Poster Section 36

Cytobia, Ltd (ASX:CYT); Market cap USD 8.5m

CYT387-elective JAK2 inhibitor to suppress the over-activity of the mutant JAK2